Safety and efficacy of imatinib (STI571) in metastatic gastrointestinal stromal tumours: a phase I study.

By A. van Oosterom, I. Judson, J. Verweij, S. Stroobants, Eugenio Donato di Paola, S. Dimitrijević, M. Martens, A. Webb, R. Sciot, M. V. Van Glabbeke and 2 more. The Lancet, 2001

1,302 citations recorded by the source corpus.

Subfields: Gastroenterology, Pulmonary and Respiratory Medicine

View Paper: https://www.semanticscholar.org/paper/644088ee9331374b9b487e5e5a49c089d257721b

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Gastroenterology

1. Christopher Corless
2. Heikki Joensuu
3. M. Heinrich

In Pulmonary and Respiratory Medicine

1. Christopher Corless
2. Heikki Joensuu
3. M. Heinrich

Citations in the corpus

• Soft Tissue Sarcomas (2001, result): “Initial results from clinical trials showed that 54% of patients with GISTs responded to imatinib therapy, with only 10% to 15% experiencing progressive disease.(113,114) However, little is known about the optimal length of treatment, the duration of benefit, or the long-term toxicity.”
• Consensus meeting for the management of gastrointestinal stromal tumors. Report of the GIST Consensus Conference of 20-21 March 2004, under the auspices of ESMO. (2005, background): “Although GIST have been resistant to conventional chemotherapy in all retrospective and prospective studies reported so far [8–12], imatinib, a tyrosine kinase inhibitor blocking most mutatedactivated KIT and PDGFRa proteins of GIST, controlled tumor growth in up to 85% of advanced GIST in the phase”
• Gastrointestinal stromal tumors: The incidence, prevalence, clinical course, and prognostication in the preimatinib mesylate era (2005, neutral): “5); OM: 0 (0) All 288 (100) 144/144 69 (10–92) Gastric (170), duodenum (13), jejunum-ileum (84), colonrectum (18), other (3) 7.”